Literature DB >> 12880584

Effects of long-term exposure to glucosamine and mannosamine on aggrecan degradation in articular cartilage.

M Z Ilic1, B Martinac, C J Handley.   

Abstract

OBJECTIVE: To investigate the effect of long-term exposure to glucosamine or mannosamine on the catabolism of aggrecan by explant cultures of bovine articular cartilage maintained in the presence of retinoic acid.
DESIGN: The kinetics of loss of 35S-labeled and total aggrecan from explant cultures of bovine articular cartilage maintained in the presence of 1 micro M retinoic acid and exposed to varying concentrations of glucosamine or mannosamine was investigated over a 9-day culture period. In other experiments, the reversibility of the inhibition of aggrecan catabolism by glucosamine or mannosamine was investigated in cultures exposed to these amino sugars for the first 5 days of a 15-day culture period. The metabolism of chondrocytes exposed to these amino sugars was evaluated by measurement of lactate production or 3H-serine and 35S-sulfate incorporation into protein and glycosaminoglycans, respectively. The direct effect of these amino sugars on soluble aggrecanase activity was determined from immunoblots of aggrecan digests.
RESULTS: Glucosamine at 5mM concentration and mannosamine at 2mM concentration inhibited degradation of radiolabeled and chemical levels of aggrecan. At concentrations of up to 10mM amino sugars, the metabolism of chondrocytes was not impaired, as determined by lactate production, protein synthesis and the incorporation of 35S-sulfate into proteoglycans. These amino sugars did not inhibit soluble aggrecanase activity. The exposure of articular cartilage explants to 5mM glucosamine or mannosamine for 5 days in culture in the presence or absence of retinoic acid did not provide long-term suppression of stimulated aggrecan loss.
CONCLUSIONS: This study indicates that continuous presence of amino sugars is required to protect cartilage from stimulated loss of aggrecan.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880584     DOI: 10.1016/s1063-4584(03)00092-x

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  7 in total

1.  Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage.

Authors:  P Patwari; G Gao; J H Lee; A J Grodzinsky; J D Sandy
Journal:  Osteoarthritis Cartilage       Date:  2005-04       Impact factor: 6.576

2.  Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness.

Authors:  B A Biggee; C M Blinn; T E McAlindon; M Nuite; J E Silbert
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

3.  10mM glucosamine prevents activation of proADAMTS5 (aggrecanase-2) in transfected cells by interference with post-translational modification of furin.

Authors:  D R McCulloch; J D Wylie; J-M Longpre; R Leduc; S S Apte
Journal:  Osteoarthritis Cartilage       Date:  2009-11-04       Impact factor: 6.576

4.  Dietary glucosamine under question.

Authors:  Jeremiah E Silbert
Journal:  Glycobiology       Date:  2009-03-02       Impact factor: 4.313

5.  Comparison of glucose derivatives effects on cartilage degradation.

Authors:  Thanyaluck Phitak; Peraphan Pothacharoen; Prachya Kongtawelert
Journal:  BMC Musculoskelet Disord       Date:  2010-07-15       Impact factor: 2.362

6.  Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation.

Authors:  Moti L Tiku; Haritha Narla; Mohit Jain; Praveen Yalamanchili
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

7.  Coculture of bovine cartilage with synovium and fibrous joint capsule increases aggrecanase and matrix metalloproteinase activity.

Authors:  Per Swärd; Yang Wang; Maria Hansson; L Stefan Lohmander; Alan J Grodzinsky; André Struglics
Journal:  Arthritis Res Ther       Date:  2017-07-05       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.